Maria Wiese

Maria Wiese

Auto-generated profile, based on publicly available information

Maria Wiese

Division of Pediatric Hematology and Oncology, Department of Child and Adolescent Health, University Medical Center Goettingen, Robert Koch Straße 40, Goettingen, Germany

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2020 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
MWMaria Wiese
Maria Wiese
FHFeda H. Hamdan
Feda H. Hamdan
KKKlaudia Kubiak
Klaudia Kubiak
CDChristopher Diederichs
Christopher Diederichs
GGGerrit H. Gielen
Gerrit H. Gielen
CKChristof M. Kramm
Christof M. Kramm
Diffuse intrinsic pontine gliomas (DIPG) are the most aggressive brain tumors in children with 5-year survival rates of only 2%. About 85% of all DIPG are characterized by a lysine-to-methionine substitution in histone 3, which leads to global H3K27 hypomethylation accompanied by H3K27 hyperacetylation. Hyperacetylation in DIPG favors the action of the Bromodomain and Extra-Terminal (BET) protein BRD4, and leads to the reprogramming of the enhancer landscape contributing to the activation of DIPG super enhancer-driven oncogenes. The activity of the acetyltransferase CREB-binding protein (CBP) is enhanced by BRD4 and associated with acetylation of nucleosomes at super enhancers (SE). In addition, CBP contributes to transcriptional activation through its function as a scaffold and protein bridge. Monotherapy with either a CBP (ICG-001) or BET inhibitor (JQ1) led to the reduction of tumor-related characteristics. Interestingly, combined treatment induced strong cytotoxic effects in H3.3K27M-mutated DIPG cell lines. RNA sequencing and chromatin immunoprecipitation revealed that these effects were caused by the inactivation of DIPG SE-controlled tumor-related genes. However, single treatment with ICG-001 or JQ1, respectively, led to activation of a subgroup of detrimental super enhancers. Combinatorial treatment reversed the inadvertent activation of these super enhancers and rescued the effect of ICG-001 and JQ1 single treatment on enhancer-driven oncogenes in H3K27M-mutated DIPG, but not in H3 wild-type pedHGG cells. In conclusion, combinatorial treatment with CBP and BET inhibitors is highly efficient in H3K27M-mutant DIPG due to reversal of inadvertent activation of detrimental SE programs in comparison with monotherapy.

2 May 2016 in Klinische Padiatrie
Verified
Journal Article
Closed access
PDF file
MWM. Wiese
M. Wiese
FSF. Schill
F. Schill
DSDominik Sturm
Dominik Sturm
Stefan PfisterStefan Pfister
Stefan Pfister
EHE. Hulleman
E. Hulleman
CKC. M. Kramm
C. M. Kramm
Background: Glioblastoma multiforme (GBM) and diffuse intrinsic pontine glioma (DIPG) belong to the most aggressive cancers in children with poor prognosis and limited therapeutic options. Therapeutic targeting of epigenetic proteins may offer new treatment options. Preclinical studies identified Enhancer of Zeste Homolog 2 (EZH2) within polycomb repressor complex 2 (PRC2) as a potential epigenetic anti-tumor target in adult GBM cells but similar inhibition studies in pediatric GBM/DIPG were still missing. Moreover, approximately 30% of pediatric high grade gliomas (pedHGG) including GBM and DIPG harbor a lysine 27 mutation (K27M) in histone 3.3 (H3.3) which is correlated with poor outcome and was shown to influence EZH2 function. Patients, materials and methods: The present study investigated the correlation of expression of EZH2 and other PRC2 genes (EZH1, SUZ12, EED) with overall survival of pediatric GBM patients and the cytotoxic impact of EZH2 inhibition by the novel agent Tazemetostat in pediatric GBM/DIPG cells harboring either a H3.3 mutation or a H3 wildtype. Results: EZH2 gene expression does not correlate with survival of pedHGG patients, and EZH2 inhibition does not induce significant cytotoxicity in pedHGG cells independently of H3.3 mutations. Discussion and conclusion: We suggest that EZH2 inhibition might not offer an effective single agent treatment option for paedHGG patients. However, the therapeutic efficacy in combination with cytotoxic and/or other epigenetically active agents still has to be elucidated. Hintergrund: Glioblastoma multiforme (GBM) und diffus, intrinsische Ponsgliome (DIPG) gehören zu den aggressivsten kindlichen Tumoren mit schlechter Prognose und limitierten Therapiemöglichkeiten. Die Inhibierung epigenetisch relevanter Proteine könnte eine neue Behandlungsoption darstellen. Vorklinische Studien identifizierten das Protein Enhancer of Zeste Homolog 2 (EZH2) des Polycomb Repressor Complex 2 (PRC2) als potentielles epigenetisches Anti-Tumortarget in adulten GBM-Zellen, entsprechende Inhibitionsexperimente in pädiatrischen GBM/DIPG fehlen jedoch bisher. Dabei tragen ca. 30% aller kindlichen hochgradigen Gliome (pädHGG) eine Mutation im Lysin 27 (K27M) des Histons 3.3 (H3.3), die ein schlechteres Überleben zu bedingen scheint und die Funktion von EZH2 beeinflusst. Patienten, Material und Methoden: Es wurde die Korrelation der Expression von EZH2 und anderer PRC2-Gene (EZH1, SUZ12, EED) mit dem Überleben pädiatrischer GBM-Patienten untersucht sowie die durch den EZH2-Inhibitor Tazemetostat vermittelte Zytotoxizität in pädiatrischen GBM/DIPG-Zellen, die ein mutiertes Histon H3.3 oder ein Wildtyp-Histon H3 tragen. Ergebnisse: Die EZH2-Genexpression korreliert nicht mit dem Überleben von pädHGG Patienten. EZH2 Inhibition induziert keine wesentliche Zytotoxizität in pädiatrischen GBM/DIPG Zelllinien, und zwar unabhängig von deren Mutationsstatus im Histon H3.3. Diskussion und Schlussfolgerung: Nach den vorliegenden Ergebnissen scheint die Inhibition von EZH2 keine vielversprechende therapeutische Option für die Monotherapie von pädiatrischen Patienten mit hochgradigen Gliomen darzustellen. Die mögliche Wirksamkeit in Kombination mit zytotoxischen und/oder anderen epigenetisch wirksamen Substanzen sollte dennoch weiter abgeklärt werden.

6 March 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
MWMaria Wiese
Maria Wiese
NWNeele Walther
Neele Walther
CDChristopher Diederichs
Christopher Diederichs
FSFabian Schill
Fabian Schill
SMSebastian Monecke
Sebastian Monecke
CKChristof M. Kramm
Christof M. Kramm
The -catenin/CBP-antagonist ICG-001 inhibits pediatric glioma tumorigenicity in a Wnt-independent manner

28 September 2023 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
EPEvangelos Prokakis
Evangelos Prokakis
SJShaishavi Jansari
Shaishavi Jansari
ABAngela Boshnakovska
Angela Boshnakovska
MWMaria Wiese
Maria Wiese
KKKathrin Kusch
Kathrin Kusch
FWFlorian Wegwitz
Florian Wegwitz
Triple-negative breast cancer (TNBC) is the most difficult breast cancer subtype to treat due to the lack of targeted therapies. Cancer stem cells (CSCs) are strongly enriched in TNBC lesions and are responsible for the rapid development of chemotherapy resistance and metastasis. Ubiquitin-based epigenetic circuits are heavily exploited by CSCs to regulate gene transcription and ultimately sustain their aggressive behavior. Therefore, therapeutic targeting of these ubiquitin-driven dependencies may reprogram the transcription of CSC and render them more sensitive to standard therapies. In this work, we identified the Ring Finger Protein 40 (RNF40) monoubiquitinating histone 2B at lysine 120 (H2Bub1) as an indispensable E3 ligase for sustaining the stem-cell-like features of the growing mammary gland. In addition, we found that the RNF40/H2Bub1-axis promotes the CSC properties and drug-tolerant state by supporting the glycolytic program and promoting pro-tumorigenic YAP1-signaling in TNBC. Collectively, this study unveils a novel tumor-supportive role of RNF40 and underpins its high therapeutic value to combat the malignant behavior of TNBC.

25 July 2023 in Journal of Traditional and Complementary Medicine
Verified
Journal Article
Open access
MWMaria Wiese
Maria Wiese
BPBente Pohlmeier
Bente Pohlmeier
KKKlaudia Kubiak
Klaudia Kubiak
FEFatma E. El-Khouly
Fatma E. El-Khouly
MSMaren Sitte
Maren Sitte
CKChristof Maria Kramm
Christof Maria Kramm
Pediatric high-grade gliomas (pedHGG) comprise a very poor prognosis. Thus, parents of affected children are increasingly resorting to complementary and alternative medicine (CAM), among those Boswellia extracts. However, nothing is known about the therapeutic effectiveness of their active substances, Boswellic acids (BA) in pedHGG. Thus, we aimed to investigate if the three main Boswellic acids (BA) present in Boswellia plants, alpha-boswellic acid (α-BA), beta-boswellic acid (β-BA) and 3-acetyl-11-keto-beta-boswellic acid (AKBA) hold any promising potential for treatment of affected pedHGG patients. Histone 3 (H3)-wildtype and H3.3K27M-mutant pedHGG cell lines were treated with BA, either alone or in combination with radio-chemotherapy with temozolomide. Cell viability, stemness properties, apoptosis, in ovo tumor growth and the transcriptome was investigated upon BA treatment. Interestingly, α-BA and β-BA treatment promoted certain tumor properties in both pedHGG cells. AKBA treatment reduced cell viability and colony growth accompanied by induction of slight anti-inflammatory effects especially in H3.3K27M-mutant pedHGG cells. However, no effects on apoptosis and in ovo tumor growth were found. In conclusion, besides positive anti-tumor effects of AKBA, tumor promoting effects were observed upon treatment with α-BA and β-BA. Thus, only pure AKBA formulations may be used to exploit any potential positive effects in pedHGG patients. In conclusion, the use of commercially available supplements with a mixture of different BA cannot be recommended due to detrimental effects of certain BA whereas pure AKBA formulations might hold some potential as therapeutic supplement for treatment of pedHGG patients.

28 April 2017 in TumorDiagnostik & Therapie
Verified
Journal Article
Closed access
PDF file
Andre von BuerenAndre von Bueren
Andre von Bueren
MWMaria Wiese
Maria Wiese
GGGerrit Gielen
Gerrit Gielen
CKChristof Maria Kramm
Christof Maria Kramm
Neben den Eckpfeilern einer konventionellen onkologischen Therapie – Tumoroperation, Radio- und Chemotherapie – beleuchtet dieser Beitrag auch zielgerichtete Therapiestrategien sowie die Neuentwicklungen im immuntherapeutischen Bereich speziell bei pädiatrischen hochgradigen Gliomen.